Chemexpress(SH:688131) Xin Lang Cai Jing·2025-10-13 02:28Group 1 - The core point of the article highlights the recent decline in the stock price of Haoyuan Pharmaceutical, which fell by 5.05% to 76.91 CNY per share, with a trading volume of 178 million CNY and a turnover rate of 1.07%, resulting in a total market capitalization of 16.313 billion CNY [1] - Haoyuan Pharmaceutical, established on September 30, 2006, and listed on June 8, 2021, specializes in the discovery of small molecule drugs, including the development of molecular building blocks and tool compounds, as well as the process development and production technology improvement of active pharmaceutical ingredients (APIs) and intermediates [1] - The company's main business revenue composition includes 68.97% from molecular building blocks, tool compounds, and biochemical reagents, with product sales accounting for 63.42%, APIs and intermediates contributing 30.46%, and technical services making up 5.55% [1] Group 2 - From the perspective of fund holdings, Haoyuan Pharmaceutical is a significant position in the Hongta Hongtu Fund, specifically in the Hongta Hongtu Medical Selected Stock A Fund (020331), which holds 13,000 shares, representing 4.93% of the fund's net value, ranking as the fourth-largest holding [2] - The Hongta Hongtu Medical Selected Stock A Fund (020331) was established on April 2, 2024, with a latest scale of 11.6663 million CNY, achieving a year-to-date return of 32.35%, ranking 1626 out of 4220 in its category, and a one-year return of 20.3%, ranking 2324 out of 3855 [2]